Importance of Shear in Prosthetic Valve Closure Dynamics

Lawrence N. Scotten, Rolland Siegel
ViVitro Systems Inc. (VSI), Victoria, BC, Canada, 90 Garibaldi Street, Lake Oswego, OR, USA

 

Background and aim of study: The results of recent hematological studies have suggested that, under non-physiological flow conditions, circulating pro-coagulant proteins activate the coagulation cascade. In the present study, in-vitro estimates of flow transients at or near the time of valve closure, including regional backflow velocity (RBV, m/s), flow acceleration (m/s2), and rate of acceleration (jerk, m/s3), have shed new light on the blood-damage potential of prosthetic valves.
Methods: Several prosthetic valves were tested in a pulse duplicator under simulated cardiac conditions. A unique prototype subsystem (LeonardoVSI) was used to measure the projected dynamic valve areas (PDVAs) from backlit valves. The regional flow velocity was derived by dividing the time-dependent volumetric flow rate by the PDVA. The flow acceleration and jerk were subsequently obtained as time derivatives of the flow velocity.
Results: Current mechanical valves have overt flow transients at valve closure, relating to leaflet non-response to flow deceleration and residual PDVA.

In contrast, tissue valves initiate closure during the flow deceleration phase, and seal when closed, thus preventing supra-physiological backflow transients. The estimated average RBV transients at or near closure ranged from 45 to 162 m/s for mechanical valves, and from 3 to 10 m/s (i.e., ca. 93% less) for tissue valves. The average derived flow acceleration and jerk transients ranged from +2,235 to -1,786×g and from +10.8 × 106 to -7.5 × 106 m/s3 for mechanical valves, respectively, and were substantially lower for tissue valves (ca. 90-99% less).
Conclusion: The study results implicate that RBV transients at or near mechanical valve closure, and not the forward or closed flow phase, as being primary to the shear-induced activation of the coagulation cascade. Results obtained in vitro for an experimental trileaflet mechanical valve (Triflo) were tested only in the aortic site similar to those obtained with tissue valves.


The Journal of Heart Valve Disease 2011;20:664-672

 
Untitled Document
Registered Users
Click here to view the file in pdf format or click here to logout from the site

Subscribers

You must be a subscriber and registered with the site to view these files. If you are a subscriber but have not yet registered with the site please click here to obtain a user name and password.

If you are an institutional user you can register your IP address with the site and will gain automatic access to all articles without a username and password.


Not yet subscribed?
Click here to subscribe using our simple online system